表型阴性心肌病变异携带者的体力活动与心血管结局
本研究基于英国生物银行84 699名参与者(含3 979名G+P-携带者),分析加速度计测量的中高强度体力活动(MVPA)与心血管结局的关系。中位随访8年发现,较高MVPA与较低心血管不良结局风险相关,且G+P-携带者与noncarrier相似;在G+P-携带者中,MVPA约100-400分钟/周时风险最低,且与心肌病发病风险降低相关,不增加恶性室性心律失常风险。
要点
- G+P-携带者较高MVPA与较低房颤、心衰、心梗、卒中风险相关。
- G+P-携带者MVPA与心脏重构模式与noncarrier相似。
- 指南推荐范围内的MVPA对G+P-携带者可能是适宜的。
核心结论
- 在G+P-携带者中,指南推荐范围内的MVPA与较低心血管不良结局风险及相似程度的心脏重构相关。
研究设计与样本
- 英国生物银行队列研究,纳入具有全基因组测序和1周加速度计体力活动数据、无 prevalent 心衰、房颤、心肌病、室性心律失常或ICD的参与者,共84 699人(平均年龄62岁,57%女性,3 979名G+P-携带者),中位随访8年。
主要发现
- 在G+P-携带者中,较高MVPA与较低心血管疾病风险相关:房颤HR 0.68(95%CI 0.58-0.79)、心衰HR 0.58(95%CI 0.47-0.71)、心梗HR 0.49(95%CI 0.24-1.00)、卒中HR 0.35(95%CI 0.12-0.99),均为最优MVPA水平对比零。
- G+P-携带者中,MVPA在100至400分钟/周范围内通常与最低风险相关。
- 在G+P-携带者中,较高MVPA与较低心肌病发病风险相关(最优MVPA对比零的HR 0.03,95%CI 0.00-0.98),且不增加室性心律失常风险(如400分钟MVPA对比零的HR 0.98,95%CI 0.83-1.14)。
- 在有心脏磁共振成像的个体中,MVPA与G+P-携带者和noncarrier相似模式和程度的心脏重构相关(如左心室扩张和左心室肥厚)。
临床怎么用
- 对于G+P-携带者,遵循指南推荐范围内的MVPA可能是适宜的,与较低心血管不良结局风险相关且不增加恶性室性心律失常风险。
局限性
- 致心律失常性右心室心肌病相关变异的估计精确度有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Exercise may lead to disease progression and higher risk of sudden death in individuals with genetic cardiomyopathies, but the effects of exercise among individuals carrying a cardiomyopathy-associated variant without clinical manifestations (G+P-) are unclear. OBJECTIVE: To examine whether the effects of moderate to vigorous physical activity (MVPA) on cardiovascular (CV) outcomes, cardiac structure and function, and risk of developing overt cardiomyopathy and malignant ventricular arrhythmias (VAs) vary by G+P- status. DESIGN, SETTING, AND PARTICIPANTS: UK Biobank participants with whole-genome sequencing providing 1 week of accelerometer-based physical activity data and without prevalent heart failure (HF), atrial fibrillation (AF), cardiomyopathy, VAs, or implantable cardioverter-defibrillators were included in this cohort study. The study was conducted at 22 assessment centers throughout the UK from February 2013 to December 2015 with a median follow-up of 8 years. Data were analyzed from March 2024 to June 2025. EXPOSURE: Accelerometer-measured MVPA (minutes/week). MAIN OUTCOMES AND MEASURES: Associations were analyzed between MVPA volume and future incidence of adverse CV outcomes (AF, HF, myocardial infarction [MI], and stroke), cardiac magnetic resonance (CMR)-based measures of cardiac remodeling, and surrogates for clinical cardiomyopathy onset (cardiomyopathy and VA). Associations were compared between G+P- carriers and noncarriers. RESULTS: Among 84 699 individuals (mean [SD] age, 62 [8] years; 48 353 [57%] women; 3979 G+P- carriers), greater MVPA was associated with a lower risk of adverse CV outcomes over a median (IQR) 8.0 (7.5-8.5) years, irrespective of genotype. In multivariable models, higher MVPA was broadly associated with lower risk of incident CV disease in G+P- carriers (hazard ratio [HR] at optimal MVPA level vs zero [95% CI], AF: 0.68 [0.58-0.79]; HF: 0.58 [0.47-0.71]; MI: 0.49, [0.24-1.00]; stroke: 0.35 [0.12-0.99]). For G+P- carriers, MVPA in the range of 100 to 400 minutes per week was generally associated with lowest risk. Among individuals with CMR imaging, MVPA was associated with a similar pattern and extent of cardiac remodeling (eg, left ventricular dilation and left ventricular hypertrophy) in G+P- carriers vs noncarriers. Among G+P- carriers, higher MVPA was associated with lower risk of incident cardiomyopathy (HR at optimal MVPA vs 0, 0.03; 95% CI, 0.00-0.98) with no increase in risk of VA (eg, HR at 400 minutes of MVPA vs 0, 0.98; 95% CI, 0.83-1.14). Findings were generally consistent across variants associated with dilated cardiomyopathy, hypertrophic cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy, although precision of estimates for arrhythmogenic right ventricular cardiomyopathy were limited. CONCLUSIONS AND RELEVANCE: In this cohort study, MVPA within the general range of guideline-based recommendations was associated with lower risk of adverse CV outcomes and similar degrees of cardiac remodeling for G+P- carriers compared to noncarriers. Findings support the appropriateness of guideline-based MVPA recommendations for G+P- carriers.
引用
- Ajufo E, Kany S, Jurgens SJ, et al. Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers. JAMA Cardiol. 2026. PMID: 41205222. doi:10.1001/jamacardio.2025.4466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。